Search hospitals

>

California

>

Loma Linda

Loma Linda University Medical Center

Claim this profile

Loma Linda, California 92354

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Brain Tumor

Conducts research for Solid Tumors

Conducts research for Neuroblastoma

449 reported clinical trials

32 medical researchers

Photo of Loma Linda University Medical Center in Loma LindaPhoto of Loma Linda University Medical Center in Loma Linda

Summary

Loma Linda University Medical Center is a medical facility located in Loma Linda, California. This center is recognized for care of Cancer, Lung Cancer, Brain Tumor, Solid Tumors, Neuroblastoma and other specialties. Loma Linda University Medical Center is involved with conducting 449 clinical trials across 936 conditions. There are 32 research doctors associated with this hospital, such as Albert Kheradpour, Hamid R. Mirshahidi, Mark E. Reeves, and Hisham Abdel-Azim, MD.

Area of expertise

1

Cancer

Global Leader

Loma Linda University Medical Center has run 58 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Lung Cancer

Global Leader

Loma Linda University Medical Center has run 47 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Loma Linda University Medical Center

Lung Cancer

Breast Cancer

Brain Tumor

Breast cancer

Cancer

Wilms Tumor

Testicular cancer

Neuroblastoma

Burkitt Lymphoma

Leukemia

Image of trial facility.

Thoracotomy vs Thoracoscopy

for Metastatic Osteosarcoma

This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

Recruiting

2 awards

Phase 3

7 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Immunotherapy Combinations

for Lung Cancer

This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered for a maximum of 108 weeks, or until confirmed disease progression per iRECIST and/ or until meeting other treatment discontinuation criteria.

Recruiting

1 award

Phase 1 & 2

5 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Loma Linda University Medical Center?

Where is Loma Linda University Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Loma Linda University Medical Center accept?

What awards or recognition has Loma Linda University Medical Center received?